<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="49153">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466334</url>
  </required_header>
  <id_info>
    <org_study_id>H-15006836</org_study_id>
    <nct_id>NCT02466334</nct_id>
  </id_info>
  <brief_title>CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients</brief_title>
  <official_title>CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has previously been shown that nitroglycerine induces cluster headache attacks in
      episodic cluster headache patients (ECH patients) in bouts but not in remission phase.
      Furthermore, plasma concentrations of calcitonin gene-related peptide (CGRP) have been shown
      to be significantly higher during, but not before and after, an attack.

      The attack appears around 20-40 min after nitroglycerine infusion with vasodilatation.
      During this latency period preceding the attack, no increase in CGRP plasma concentrations
      is seen. CGRP induces migraine attacks in 65% of migraine patients, and CGRP antagonists as
      well as monoclonal antibodies against CGRP are effective in migraine treatment.

      Based on the above the investigators hypothesize the following:

        1. Provoking ECH patients in bout with CGRP triggers cluster headache attacks

        2. Provoking ECH patients in remission with CGRP does not trigger cluster headache attacks

        3. Provoking chronic cluster headache patients with CGRP triggers cluster headache attacks
           more often than in ECH patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in occurence of cluster headache attacks</measure>
    <time_frame>One hour after administration of study drug</time_frame>
    <description>Using a 24 hour headache questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC headache</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to maximum headache score after CGRP vs. placebo</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Cluster Headache</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5µg/min IV calcitonin-gene related peptide for 20 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV placebo for 20 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcitonin-Gene Related Peptide</intervention_name>
    <description>1,5 µg/min of IV CGRP over 20 mins</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>CGRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>40 ml of normal saline over 20 mins</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfillment of IHS criteria for cluster headache either chronic or episodic

          -  Patients in bouts 1-32 attacks per week

          -  Patients in remission minimum of 1 month remission time

          -  fertile women must use safe contraception

        Exclusion Criteria:

          -  All other primary types of headache

          -  daily intake of medication other than Verapamil and oral contraceptives

          -  headache 8 hours or less before study day begins

          -  intake of any drug other than mentioned above less than four times half life of the
             drug on study day

          -  pregnant or lactating women

          -  any history or clinical sigs of hyper/hypotension, heart disease, mental disorder,
             substance abuse, or other illness deemed relevant by the medical doctor assessing the
             patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Messoud Ashina, MD, PhD,DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luise H Vollesen, MD</last_name>
    <email>luisevollesen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agneta H Snoer, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Copenhagen</city>
        <state>Glostrup</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song Guo, MD</last_name>
      <phone>+45 38633470</phone>
      <email>song.guo.01@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 12, 2017</lastchanged_date>
  <firstreceived_date>May 21, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Song Guo</investigator_full_name>
    <investigator_title>Medical doctor, Ph.d. student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Cluster Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
